StockNews.AI
RPRX
StockNews.AI
120 days

Royalty Pharma Declares Second Quarter 2025 Dividend

1. RPRX declared a $0.22 dividend for Q2 2025, payable June 10. 2. The dividend reflects RPRX's strong financial health and commitment to shareholders. 3. RPRX holds royalties on over 35 leading biopharmaceutical products. 4. Royalty Pharma funds innovation via partnerships and royalty acquisitions. 5. Key products include Vertex’s Trikafta and GSK’s Trelegy.

3m saved
Insight
Article

FAQ

Why Bullish?

The dividend payment indicates a strong financial position. Similar companies see positive price movements post-dividend announcements.

How important is it?

The dividend announcement signals confidence in sustained profitability, influencing investor sentiment and stock demand.

Why Short Term?

The imminent dividend payment creates immediate investor interest, potentially boosting stock prices.

Related Companies

VRTXGSKJNJBIIB
April 21, 2025 16:15 ET  | Source: Royalty Pharma plc NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications +1 (212) 883-6637ir@royaltypharma.com

Related News